Skip to main content
Nykode Therapeutics ASA logo

Nykode Therapeutics ASA — Investor Relations & Filings

Ticker · NYKD ISIN · NO0010714785 LEI · 254900UKQHWYZJD22017 OL Manufacturing
Open in API
Filings indexed 493 across all filing types
Latest filing 2021-02-05 Board/Management Inform…
Country NO Norway
Listing OL NYKD

About Nykode Therapeutics ASA

https://nykode.com/

Nykode Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company's core is its proprietary Vaccibody™ technology, a modular platform designed to create targeted vaccines. This technology works by linking antigens to a targeting unit, which delivers them directly to antigen-presenting cells. This mechanism is engineered to induce rapid, potent, and long-lasting T-cell and antibody immune responses. Nykode's development pipeline is focused on generating therapeutics for a range of diseases, with a primary emphasis on oncology and infectious diseases.

Recent filings

Filing Released Lang Actions
Vaccibody will recruit new CFO
Board/Management Information Classification · 98% confidence The document is a formal company announcement titled 'Vaccibody will recruit new CFO'. It explicitly states that the current CFO is stepping down and the company is searching for a replacement, contracting an interim CFO in the meantime. This content directly relates to changes in senior management personnel. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document length is short (3026 chars), but its primary content is the announcement itself, not a notice about publishing a separate report, making MANG the most appropriate classification.
2021-02-05 English
Vaccibody will recruit new CFO
Board/Management Information Classification · 98% confidence The document is a short press release announcing a change in senior management: the current CFO is stepping down, and the company is initiating a search for a replacement, contracting an interim CFO in the meantime. This directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in senior management.
2021-02-05 English
Financial calendar
Report Publication Announcement Classification · 99% confidence The document is titled 'Financial calendar' and lists future dates for various corporate reports such as 'Annual Report', 'Half-yearly Report', and 'Quarterly Report'. It is not the report itself, but rather an announcement detailing *when* reports will be published. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. The document is very short (437 characters), supporting the 'MENU VS MEAL' rule, indicating it's an announcement rather than the full report.
2021-01-27 English
Share capital increase from exercise of warrants
Share Issue/Capital Change Classification · 98% confidence The document explicitly states 'Share capital increase from exercise of warrants' and details the resulting change in share capital (from NOK 2,845,376.80 to NOK 2,847,851.80) and the increase in the number of outstanding shares (from 284,537,680 to 284,785,180). This directly relates to a change in the company's capital structure due to the issuance of new shares via warrant exercise. This aligns perfectly with the definition for Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). Since it details the specific change in the number of shares and capital amount resulting from an exercise, SHA (Share Issue/Capital Change) is the most precise fit, although CAP is also relevant. I will select SHA as it is more specific to the mechanics described.
2020-12-30 English
Vaccibody - Mandatory notification of intra group transfer of shares by primary insider
Major Shareholding Notification Classification · 99% confidence The document explicitly states it is a 'Mandatory notification of intra group transfer of shares by primary insider'. It details a transaction where shares were bought by one entity (Datum AS) from another (Datum Opportunity AS), both linked to a board member (Jan Haudemann-Andersen). This type of transaction report by directors/executives regarding their personal or closely related holdings falls directly under the definition of Director's Dealing (insider trades). The code for this is DIRS.
2020-12-11 English
Mandatory notification of intra group transfer of shares by primary insider’s related party
Major Shareholding Notification Classification · 99% confidence The document explicitly details transactions involving shares bought by RASMUSSENGRUPPEN AS from its wholly owned subsidiaries. It concerns the holdings of a primary insider's related party (Trygve Lauvdal is a board member and employee of a related entity). This type of notification regarding personal share transactions by directors and executives (insider trades) aligns directly with the definition of Director's Dealing (DIRS). Although it involves share transfers, the context is mandatory notification related to an insider's interest, not a general share repurchase (POS) or capital change (SHA).
2020-12-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.